In our study, we firstly pioneer the usage of large-scale pan-cancer scRNA-seq and RNA-seq immunotherapy datasets to develop and validate the pan-cancer STMN2.SIG for predicting immunotherapy response through ML approaches. This evidence concerns the gene STMN2 and cancer.